Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q2 2024

Q2 2024 biggest moves
  • GILDGILD

    Gilead Sciences

    New

    1.7% of portfolio

  • SWTXSWTX

    SPRINGWORKS THERAPEUTICS

    Sold out

    was 1.1% of portfolio

  • CVSCVS

    CVS Health

    New

    1.0% of portfolio

  • BAXBAX

    Baxter International

    257× the shares

    now 0.9% of portfolio

556 changes in all

Top Holdings433 positions

Checking export access…
Activity:
NUVL
NUVLDelisted

NUVALENT INC

20M$1.5B25.2%——
12 qtrssince 2021-Q3
Unchanged
0
??
INSMED INCDelisted
Bond
151.4M$258.7M4.3%——
18 qtrssince 2020-Q1
Increased
71
VTRS

Viatris Inc.

21.4M$227.4M3.8%$11.22-13.58%
15 qtrssince 2020-Q4
Increased
56
CNC

Centene Corporation

2.7M$175.7M2.9%$67.97-2.46%
19 qtrssince 2019-Q4
Increased
58
174.4M$164.5M2.7%——
2 qtrssince 2024-Q1
Increased
77
161.9M$163.3M2.7%——
7 qtrssince 2022-Q4
Unchanged
0
MRUS
MRUSDelisted

MERUS N V

2.7M$162.7M2.7%——
11 qtrssince 2021-Q4
Increased
54
LRMR

Larimar Therapeutics, Inc.

21.2M$153.9M2.6%$6.64+9.20%
17 qtrssince 2020-Q2
Unchanged
0
CPRX
CPRXDelisted

CATALYST PHARMACEUTICALS INC

9.1M$141.4M2.4%——
8 qtrssince 2022-Q3
Decreased
0
AHCO

AdaptHealth Corp.

13.3M$132.6M2.2%$18.05-44.59%
19 qtrssince 2019-Q4
Unchanged
0
RVMD

Revolution Medicines, Inc.

3.1M$119.9M2.0%$26.00+49.28%
18 qtrssince 2020-Q1
Unchanged
0
??
ACCOLADE INCDelisted
Bond
132.6M$115.5M1.9%——
9 qtrssince 2022-Q2
Unchanged
0
SGRY

Surgery Partners, Inc.

4.7M$112M1.9%$28.00-15.02%
4 qtrssince 2023-Q3
Increased
65
KURA

Kura Oncology, Inc.

5.4M$111.4M1.9%$14.13+45.71%
13 qtrssince 2021-Q2
Unchanged
0
OSCR

Oscar Health, Inc.

7M$110.1M1.8%$9.15+72.90%
3 qtrssince 2023-Q4
Decreased
0
BKD

Brookdale Senior Living Inc.

15.6M$106.6M1.8%$4.41+54.86%
19 qtrssince 2019-Q4
Unchanged
0
WAY

Waystar Holding Corp.

5M$106.5M1.8%$21.500.00%
1 qtr
New
69
GILD

Gilead Sciences, Inc.

1.5M$102.3M1.7%$64.42+23.34%
1 qtr
New
68
NBIX

Neurocrine Biosciences, Inc.

691,004$95.1M1.6%$95.92+43.52%
14 qtrssince 2021-Q1
Unchanged
0
SPRY

ARS Pharmaceuticals, Inc.

11.1M$94.3M1.6%$8.53-0.23%
7 qtrssince 2022-Q4
Unchanged
0
$6B
AUM
433
Positions
Q2 2024
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2023-Q1$4,485,670,170-7.14836619832%
2023-Q2$4,684,196,2414.42578396262%
2023-Q3$4,538,793,245-3.10411836992%
2023-Q4$5,415,638,75919.3189129063%
2024-Q1$5,748,069,8946.13835504533%
2024-Q2$6,010,510,6294.56571927342%
Activity profile
$ moved · Q2'24
New31%Increased35%Decreased10%Exited24%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.9 quarters
<1Q42%1-4Q39%1-2Y4%2Y+15%

Deerfield Management Company, L.P. manages $6B across 433 positions as of Q2 2024. Top holdings: NUVL (25.2%), INSMED INC (4.3%), VTRS (3.8%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$6B
NUVL25.23%
INSMED INC4.30%
VTRS3.78%
CNC2.92%
INTEGRA LIFE2.74%
BROOKDALE SR2.72%
MRUS2.71%
LRMR2.56%
CPRX2.35%
AHCO2.21%
Other2.00%

Portfolio allocation by GICS sector

Sectors11
Healthcare95.30%
Unknown1.78%
Technology0.65%
Industrials0.51%
Financial Services0.50%
Consumer Defensive0.38%
Consumer Cyclical0.36%
Real Estate0.14%
Basic Materials0.14%
Communication Services0.10%
Other0.13%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used